“This Gilead trial is actually the best-case scenario, hugely positive and the market should be up a lot,” said Richard Tan, a director at PanAgora Asset Management in Boston, who leads the stock selector equity team. “Just yesterday we were still tentative on whether the market might revisit March lows, but now we can probably say that we’ve seen the lows in the market.”

View Here